首页> 外文期刊>BMC Biotechnology >Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct
【24h】

Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct

机译:使用tCD2-萤光素酶嵌合构建体快速获得稳定的生物发光肿瘤细胞系

获取原文
           

摘要

Background Bioluminescent tumor cell lines are experimental tools of major importance for cancer investigation, especially imaging of tumors in xenografted animals. Stable expression of exogenous luciferase in tumor cells combined to systemic injection of luciferin provides an excellent signal/background ratio for external optical imaging. Therefore, there is a need to rationalize and speed up the production of luciferase-positive tumor cell lines representative of multiple tumor phenotypes. For this aim we have designed a fusion gene linking the luciferase 2 protein to the c-terminus of a truncated form of the rat CD2 protein ( tCD2-luc2 ). To allow simultaneous assessment of the wild-type luciferase 2 in a context of tCD2 co-expression, we have made a bicistronic construct for concomitant but separate expression of these two proteins ( luc2- IRES -tCD2 ). Both the mono- and bi-cistronic constructs were transduced in lymphoid and epithelial cells using lentiviral vectors. Results The tCD2-luc2 chimera behaves as a type I membrane protein with surface presentation of CD2 epitopes. One of these epitopes reacts with the OX34, a widely spread, high affinity monoclonal antibody. Stably transfected cells are sorted by flow cytometry on the basis of OX34 staining. In vitro and, moreover, in xenografted tumors, the tCD2-luc2 chimera retains a substantial and stable luciferase activity, although not as high as the wild-type luciferase expressed from the luc2- IRES -tCD2 construct. Expression of the tCD2-luc2 chimera does not harm cell and tumor growth. Conclusion Lentiviral transduction of the chimeric tCD2-luc2 fusion gene allows selection of cell clones with stable luciferase expression in less than seven days without antibiotic selection. We believe that it will be helpful to increase the number of tumor cell lines available for in vivo imaging and assessment of novel therapeutic modalities. On a longer term, the tCD2-luc2 chimera has the potential to be expressed from multi-cassette vectors in combination with various inserts of interest.
机译:背景技术生物发光肿瘤细胞系是对癌症研究尤其是对异种移植动物中的肿瘤成像特别重要的实验工具。外源荧光素酶在肿瘤细胞中的稳定表达与系统注射荧光素相结合,为外部光学成像提供了极好的信号/背景比。因此,需要合理化并加速代表多种肿瘤表型的萤光素酶阳性肿瘤细胞系的产生。为了这个目标,我们设计了一种融合基因,将荧光素酶2蛋白连接到大鼠CD2蛋白(tCD2-luc2)的截短形式的c末端。为了在tCD2共表达的背景下同时评估野生型荧光素酶2,我们制作了双顺反子构建体,用于同时但单独表达这两种蛋白(luc2- IRES -tCD2)。使用慢病毒载体在淋巴样和上皮细胞中转导了单顺反子和双顺反子构建体。结果tCD2-luc2嵌合体表现为具有CD2表位表面表现的I型膜蛋白。这些表位之一与OX34反应,OX34是一种广泛传播的高亲和力单克隆抗体。在OX34染色的基础上,通过流式细胞术对稳定转染的细胞进行分选。在体外,以及在异种移植肿瘤中,tCD2-luc2嵌合体保留了基本且稳定的荧光素酶活性,尽管不如从luc2-IRES -tCD2构建体表达的野生型荧光素酶高。 tCD2-luc2嵌合体的表达不会损害细胞和肿瘤的生长。结论嵌合tCD2-luc2融合基因的慢病毒转导可在不到7天的时间内选择具有稳定荧光素酶表达的细胞克隆,而无需选择抗生素。我们认为,增加可用于体内成像和评估新型治疗方式的肿瘤细胞系的数量将是有帮助的。从长远来看,tCD2-luc2嵌合体具有与多种目的插入物结合的多盒载体表达的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号